Cardiovascular effects of apelin infusion in healthy male subjects

Cardiovascular effects of apelin infusion in healthy male subjects - Cardiovascular effects of apelin infusion

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39109

Enrollment

Registered

2012-06-27

Start date

2012-07-25

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovasculaire ziekten heart- and bloodvessel diseases

Interventions

In the first period the subjects will receive 3 different infusions: - Apelin will be administrated by infusion at 3 dose levels (0.3, 3.0 and 30 nmol/min) for 30 minutes each. - SNP will be adminis

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: healthy male subjects 18-55 yrs, inclusive BMI: 18.5-30.0 kg/m2, inclusive non-smoking or less than 10 cigarettes/day

Exclusion criteria

Exclusion criteria: Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study

Design outcomes

Primary

Measure	Time frame
Pharmacodynamics: hemodynamic assessments, cardiac index, ATII pressor test, NE pressor test and Glomerular Filtration Rate (GFR) Pharmacokinetics: plasma apelin and iohexol concentrations, pharmacokinetic parameters Safety: adverse events, vital signs, ECG-parameters, laboratory parameters, physical examination	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)